Sugi Predict

Sugi Predict / Compounds / SCHEMBL3580133

SCHEMBL3580133

SCHEMBL3580133

CCn1ncc(C(=O)O)c1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.54
▸ SMN1; SMN2 Q16637 6/20 0.52
▸ ALDH1A1 P00352 5/20 0.52
▸ RAB9A P51151 3/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ HTT P42858 3/20 0.51
▸ HPGD P15428 3/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ GAA P10253 4/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ POLB P06746 1/20 0.44
▸ APOBEC3A P31941 1/20 0.44
▸ BLM P54132 1/20 0.44
▸ APOBEC3G Q9HC16 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ NR4A3 Q92570 1/20 0.42
▸ SPR P35270 1/20 0.41
▸ MEN1 O00255 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334488 0.85 LMNA (0.54) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL26418189 0.83 LMNA (0.52) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL4716984 0.82 AGTR1 (0.42) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL6052434 0.81 KDM4E (0.41) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL15565711 0.81 NPC1 (0.46) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL13462878 0.80 SMN1; SMN2 (0.58) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL841372 0.80 LMNA (0.54) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL6156758 0.80 KDM4E (0.41) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL4968650 0.79 POLB (0.42) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2
SCHEMBL2806923 0.79 ALDH1A1 (0.45) LMNASMN1; SMN2ALDH1A1RAB9ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 — — EP claimed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 — — EP claimed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 — — EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 — — US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 — — WO claimed
WO-2025105858-A1 HETEROARYL-DERIVATIVE COMPOUND AND USE THEREOF (주)신테카바이오 2025-05-22 — — WO disclosed
WO-2025068514-A1 SUBSTITUTED HETEROCYCLIC CARBOXAMINDES AND USE THEREOF BAYER AKTIENGESELLSCHAFT (DE) 2025-04-03 — — WO disclosed
US-20230167094-A1 H4 ANTAGONIST COMPOUNDS HEPTARES THERAPEUTICS LIMITED (GB) 2023-06-01 — — US disclosed
CN-113891749-A Quinoline derivatives and their use for the treatment of cancer 埃皮齐梅股份有限公司 2022-01-04 — — CN disclosed
US-10344026-B2 Compositions and methods of targeting mutant K-ras NANTBIO, INC. (US) 2019-07-09 — — US disclosed
US-20180201610-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS NANTBIO, INC. 2018-07-19 — — US disclosed
EP-2200440-B1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS CRESTONE INC (US) 2017-07-19 — — EP disclosed
EP-2200440-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS Crestone, Inc. (US) 2010-06-30 — — EP disclosed
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 — — US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 — — US disclosed
WO-2009015208-A1 ANTIBACTERIAL AMIDE AND SULFONAMIDE SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS REPLIDYNE, INC. (US) 2009-01-29 — — WO disclosed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 — — EP disclosed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 — — US disclosed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 LMNA 4717/4885SMN1; SMN2 4781/4885ALDH1A1 2605/4885
US-10344026-B2 Compositions and methods of targeting mutant K-ras KRAS, NRAS, HRAS LMNA 2729/4885SMN1; SMN2 3468/4885ALDH1A1 4472/4885
US-20180201610-A1 COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS KRAS, NRAS, HRAS LMNA 2729/4885SMN1; SMN2 3468/4885ALDH1A1 4472/4885
US-20230167094-A1 H4 ANTAGONIST COMPOUNDS HRH4, HRH3, HRH2 LMNA 4644/4885SMN1; SMN2 3911/4885ALDH1A1 3149/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 LMNA 4604/4885SMN1; SMN2 4664/4885ALDH1A1 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.